That WISP2 has been reported to be possibly regulated by the typical Wnt and TGF-β pathways for treatment of obesity and metabolic diseases, and developing new therapeutic strategies (Grünberg et al., 2018). Here, TGFB1 is linked to obesity due to melanocortin 4 receptor deficiency.